Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.33 |
| ▸ | PPARG | P37231 | 7/20 | 0.33 |
| ▸ | PPARD | Q03181 | 7/20 | 0.33 |
| ▸ | PPARA | Q07869 | 7/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16667226 | 1.00 | EP300 (0.36) | EP300AKR1B1ALOX15GPR84PPARG | |
| SCHEMBL16667225 | 1.00 | EP300 (0.36) | EP300AKR1B1ALOX15GPR84PPARG | |
| SCHEMBL16671260 | 0.82 | EP300 (0.41) | EP300ALOX15PPARGPPARDPPARA | |
| SCHEMBL16671258 | 0.82 | EP300 (0.41) | EP300ALOX15PPARGPPARDPPARA | |
| SCHEMBL16671256 | 0.82 | EP300 (0.41) | EP300ALOX15PPARGPPARDPPARA | |
| SCHEMBL8002430 | 0.75 | AKR1B1 (0.39) | AKR1B1ALOX15GPR84PPARGPPARD | |
| SCHEMBL727984 | 0.74 | AKR1B1 (0.42) | AKR1B1ALOX15GPR84PPARGPPARD | |
| SCHEMBL9464116 | 0.72 | ALDH1A1 (0.30) | TSHRALDH1A1 | |
| SCHEMBL9464106 | 0.72 | ALDH1A1 (0.30) | TSHRALDH1A1 | |
| SCHEMBL6012107 | 0.71 | AKR1B1 (0.36) | EP300AKR1B1ALOX15GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060571-B1 | PROCESS FOR THE RUTHENIUM CATALYZED TRANS-SELECTIVE HYDROSTANNATION OF ALKYNES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-12-06 | — | — | EP | disclosed |
| US-9556209-B2 | Process for the ruthenium catalyzed trans-selective hydrostannation of alkynes | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20160251382-A1 | PROCESS FOR THE RUTHENIUM CATALYZED TRANS-SELECTIVE HYDROSTANNATION OF ALKYNES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3060571-A1 | PROCESS FOR THE RUTHENIUM CATALYZED TRANS-SELECTIVE HYDROSTANNATION OF ALKYNES | Studiengesellschaft Kohle MbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015059006-A1 | PROCESS FOR THE RUTHENIUM CATALYZED TRANS-SELECTIVE HYDROSTANNATION OF ALKYNES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-04-30 | — | — | WO | disclosed |
| EP-2865684-A1 | Process for the ruthenium catalyzed trans-selective hydrostannation of alkynes | Studiengesellschaft Kohle mbH (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| EP-1660511-B1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2010-11-03 | — | — | EP | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | EP300 2086/4885AKR1B1 2836/4885ALOX15 4179/4885 |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | NME1, NME2, NTPCR | EP300 1103/4885AKR1B1 3429/4885ALOX15 3660/4885 |
| US-20160251382-A1 | PROCESS FOR THE RUTHENIUM CATALYZED TRANS-SELECTIVE HYDROSTANNATION OF ALKYNES | ADH4, HRH4, POR | EP300 3305/4885AKR1B1 113/4885ALOX15 1380/4885 |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | EP300 2086/4885AKR1B1 2836/4885ALOX15 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.